公众对痴呆症真正知道什么? 在土耳其,基于社区的横截面调查
Merve Aliye Akyol1, Seda Güney2, Ecem Özgül3
1Department of Internal Medicine Nursing, Faculty of Nursing, Dokuz Eylul University, Izmir, Turkey.
Public health nursing (Boston, Mass.)
|August 28, 2024
概括
土耳其公众对痴呆症的了解很低,在痴呆症知识评估尺度上有很多错误的答案. 诸如年龄和先前教育等因素会影响理解,强调有针对性的公共卫生倡议的必要性.
科学领域:
- 老年学是一门学科.
- 公共卫生 公共卫生
- 认知科学 认知科学
背景情况:
- 痴呆症是一个日益增长的全球健康挑战.
- 对于土耳其公众来说,没有先前对痴呆症知识的评估.
研究的目的:
- 评估土耳其人口对痴呆症的知识水平.
- 确定影响公众对痴呆症理解的因素.
主要方法:
- 对1106名参与者进行了以社区为基础的横截面调查.
- 使用了土耳其版的痴呆症知识评估量表 (DKAS-T).
- 数据分析涉及描述性统计,相关性和多重回归.
主要成果:
- 在34分中,DKAS-T平均得分为12.32±6.05.
- 参与者正确回答了不到一半的痴呆症知识项.
- 高度痴呆知识的预测因素包括年龄较小,先前的教育,照顾经验和与痴呆症患者的互动.
结论:
- 土耳其公众对痴呆症的了解非常有限.
- 有针对性的教育计划对于改善公众对痴呆症的理解至关重要.
- 干预措施应解决DKAS-T发现的特定知识差距.
相关概念视频
Dementia
107
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
107
Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170


